1 – 37 of 37
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study
(
- Contribution to journal › Article
- 2023
-
Mark
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
(
- Contribution to journal › Article
-
Mark
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Clinical effects of Lewy body pathology in cognitively impaired individuals
(
- Contribution to journal › Article
-
Mark
Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
(
- Contribution to journal › Article
- 2022
-
Mark
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
(
- Contribution to journal › Article
-
Mark
Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders
(
- Contribution to journal › Article
-
Mark
Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain : associations with pain severity and central sensitization
(
- Contribution to journal › Article
- 2021
-
Mark
Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease
(
- Contribution to journal › Article
- 2020
-
Mark
Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders
(
- Contribution to journal › Article
-
Mark
Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype
(
- Contribution to journal › Article
- 2019
-
Mark
Diffusion tensor MRI to distinguish progressive supranuclear palsy from a-synucleinopathies
(
- Contribution to journal › Article
-
Mark
A quick test of cognitive speed can predict development of dementia in Parkinson’s disease
(
- Contribution to journal › Article
- 2018
-
Mark
Tidig diagnos och behandling med gallsyra avgörande vid cerebrotendinös xantomatos
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
(
- Contribution to journal › Article
-
Mark
Alteration of putaminal fractional anisotropy in Parkinson’s disease : a longitudinal diffusion kurtosis imaging study
(
- Contribution to journal › Article
- 2017
-
Mark
Biomarkers in Parkinson's disease and related disorders. Diagnostic value of biochemical markers and their relation to disease progression
2017)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Blood-based NfL : A biomarker for differential diagnosis of parkinsonian disorder
(
- Contribution to journal › Article
- 2016
-
Mark
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
2016) In Movement Disorders(
- Contribution to journal › Article
-
Mark
Alterations of diffusion kurtosis and neurite density measures in deep grey matter and white matter in Parkinson's disease
(
- Contribution to journal › Article
- 2015
-
Mark
The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
(
- Contribution to journal › Article
-
Mark
Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy.
(
- Contribution to journal › Article
-
Mark
CSF biomarkers and clinical progression of Parkinson disease.
(
- Contribution to journal › Article
-
Mark
Increased CSF biomarkers of angiogenesis in Parkinson disease.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients.
(
- Contribution to journal › Article
- 2014
-
Mark
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies.
2014) In Journal of Alzheimer's Disease(
- Contribution to journal › Article
- 2013
-
Mark
Proinflammatory cytokines are elevated in serum of patients with multiple system atrophy.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid inflammatory markers in Parkinson's disease - Associations with depression, fatigue, and cognitive impairment.
(
- Contribution to journal › Article
-
Mark
A beta 1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases
(
- Contribution to journal › Article
-
Mark
Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy.
(
- Contribution to journal › Article
- 2012
-
Mark
Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum.
(
- Contribution to journal › Article
-
Mark
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
(
- Contribution to journal › Article